{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:27:52Z","timestamp":1770823672406,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Cefepime, a cornerstone antibiotic in critical care, is associated with underrecognized cefepime-induced neurotoxicity (CIN), particularly in patients 65 years old and older. The true incidence is unknown due to inconsistent monitoring and a lack of diagnostic criteria. The recent Antibiotic Choice on Renal Outcomes (ACORN) trial underscored CIN\u2019s clinical significance, finding that cefepime recipients experienced 21% fewer delirium- and coma-free days than those on piperacillin-tazobactam. Current guidelines lack active surveillance recommendations, leading to delayed diagnosis and intervention. We propose three informatics-based strategies to address these challenges: 1) electronic health record (EHR)-integrated datasets utilizing machine learning and natural language processing to identify CIN at scale, 2) automated electroencephalogram tools to provide real-time alerts to clinicians, and 3) dynamic risk scores that continuously update from EHR data to guide prescribing. Implementing these safeguards to optimize CIN prevention, which may be relevant for other antibiotics with neurotoxicity risk, can improve neurologic outcomes and patient safety in critically ill populations.<\/jats:p>","DOI":"10.1097\/cce.0000000000001380","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:00:08Z","timestamp":1770822008000},"page":"e1380","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Strategies for Safer Cefepime Use to Prevent Neurotoxicity Using the Electronic Health Record"],"prefix":"10.1097","volume":"8","author":[{"given":"Sahar F.","family":"Zafar","sequence":"first","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA."},{"name":"Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemi","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA."},{"name":"Vaccine and Immunotherapy Center, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa R.","family":"Letourneau","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA."},{"name":"Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex E.","family":"Rock","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA."},{"name":"Department of Pharmacy, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Brandon","family":"Westover","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA."},{"name":"Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5677-6954","authenticated-orcid":false,"given":"Shibani S.","family":"Mukerji","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA."},{"name":"Harvard Medical School, Boston, MA."},{"name":"Vaccine and Immunotherapy Center, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA."},{"name":"Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"R1-20260211","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jac\/dkaa511","article-title":"An update on cefepime and its future role in combination with novel \u03b2-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.","volume":"76","author":"Isler","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R2-20260211","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/jamainternmed.2016.5651","article-title":"Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012.","volume":"176","author":"Baggs","year":"2016","journal-title":"JAMA Intern Med"},{"key":"R3-20260211","doi-asserted-by":"crossref","first-page":"e2411919121","DOI":"10.1073\/pnas.2411919121","article-title":"Global trends in antibiotic consumption during 2016\u20132023 and future projections through 2030.","volume":"121","author":"Klein","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R4-20260211","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/cid\/ciaa373","article-title":"Antimicrobial use in US hospitals: Comparison of results from emerging infections program prevalence surveys, 2015 and 2011.","volume":"72","author":"Magill","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R5-20260211","doi-asserted-by":"crossref","first-page":"ofab236","DOI":"10.1093\/ofid\/ofab236","article-title":"Trends in antibiotic use in United States hospitals during the coronavirus disease 2019 pandemic.","volume":"8","author":"Rose","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R7-20260211","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1093\/jac\/dkac271","article-title":"Cefepime-induced neurotoxicity: Systematic review.","volume":"77","author":"Maan","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R8-20260211","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s12028-020-01074-3","article-title":"Updated nomenclature of delirium and acute encephalopathy.","volume":"33","author":"Slooter","year":"2020","journal-title":"Neurocrit Care"},{"key":"R9-20260211","doi-asserted-by":"crossref","first-page":"74","DOI":"10.18700\/jnc.190109","article-title":"Cefepime-induced neurotoxicity.","volume":"12","author":"Lee","year":"2019","journal-title":"J Neurocrit Care"},{"key":"R11-20260211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: A systematic review.","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"key":"R12-20260211","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/archneurol.2011.204","article-title":"Continuous epileptiform discharges in patients treated with cefepime or meropenem.","volume":"68","author":"Naeije","year":"2011","journal-title":"Arch Neurol"},{"key":"R13-20260211","doi-asserted-by":"crossref","first-page":"e40384","DOI":"10.2196\/40384","article-title":"Development and evaluation of a natural language processing annotation tool to facilitate phenotyping of cognitive status in electronic health records: Diagnostic study.","volume":"24","author":"Noori","year":"2022","journal-title":"J Med Internet Res"},{"key":"R14-20260211","first-page":"e40980","article-title":"The trend of cefepime-induced neurotoxicity: A systematic review.","volume":"15","author":"Ajibola","year":"2023","journal-title":"Cureus"},{"key":"R15-20260211","first-page":"23247096241259536","article-title":"Cefepime neurotoxicity in patients with normal renal function: An overlooked cause of encephalopathy in the intensive care unit.","volume":"12","author":"Alagha","year":"2024","journal-title":"J Investig Med High Impact Case Rep"},{"key":"R16-20260211","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s12028-020-01035-w","article-title":"Cefepime is associated with acute encephalopathy in critically ill patients: A retrospective case-control study.","volume":"33","author":"Singh","year":"2020","journal-title":"Neurocrit Care"},{"key":"R17-20260211","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2023.20583","article-title":"Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: The ACORN randomized clinical trial.","volume":"330","author":"Qian","year":"2023","journal-title":"JAMA"},{"key":"R18-20260211","first-page":"NA56674","article-title":"Is piperacillin-tazobactam more likely than cefepime to be associated with acute kidney injury?","author":"Brett","year":"2023","journal-title":"NEJM J Watch"},{"key":"R19-20260211","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2146\/ajhp160096","article-title":"Impact of an antimicrobial stewardship initiative on time to administration of empirical antibiotic therapy in hospitalized patients with bacteremia.","volume":"74","author":"Bias","year":"2017","journal-title":"Am J Health Syst Pharm"},{"key":"R20-20260211","doi-asserted-by":"crossref","first-page":"dlac043","DOI":"10.1093\/jacamr\/dlac043","article-title":"Therapeutic drug monitoring of cefepime in a non-critically ill population: Retrospective assessment and potential role for model-based dosing.","volume":"4","author":"Suttels","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"R21-20260211","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmi.2019.06.028","article-title":"Cefepime neurotoxicity: Thresholds and risk factors. A retrospective cohort study.","volume":"26","author":"Boschung-Pasquier","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R22-20260211","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/AAC.01595-08","article-title":"High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.","volume":"54","author":"Lamoth","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20260211","doi-asserted-by":"crossref","first-page":"R264","DOI":"10.1186\/cc13094","article-title":"Cefepime neurotoxicity in the intensive care unit: A cause of severe, underappreciated encephalopathy.","volume":"17","author":"Fugate","year":"2013","journal-title":"Crit Care"},{"key":"R24-20260211","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3988\/jcn.2020.16.3.408","article-title":"Cefepime-induced encephalopathy in a tertiary medical center in Korea.","volume":"16","author":"Jeon","year":"2020","journal-title":"J Clin Neurol"},{"key":"R25-20260211","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00134-001-1170-9","article-title":"Cefepime-induced neurotoxicity: An underestimated complication of antibiotherapy in patients with acute renal failure.","volume":"28","author":"Chatellier","year":"2002","journal-title":"Intensive Care Med"},{"key":"R26-20260211","first-page":"312","article-title":"Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: Seizures associated with cefepime.","volume":"14","author":"Smith","year":"2012","journal-title":"Crit Care Resusc"},{"key":"R27-20260211","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ana.26060","article-title":"Electroencephalographic abnormalities are common in COVID-19 and are associated with outcomes.","volume":"89","author":"Lin","year":"2021","journal-title":"Ann Neurol"},{"key":"R28-20260211","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12028-022-01442-1","article-title":"Incidence and predictive factors associated with beta-lactam neurotoxicity in the critically ill: A retrospective cohort study.","volume":"37","author":"Haddad","year":"2022","journal-title":"Neurocrit Care"},{"key":"R29-20260211","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12028-015-0151-8","article-title":"Response rates to anticonvulsant trials in patients with triphasic-wave EEG patterns of uncertain significance.","volume":"24","author":"O\u2019Rourke","year":"2016","journal-title":"Neurocrit Care"},{"key":"R30-20260211","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1212\/WNL.0b013e3182735cd7","article-title":"Generalized periodic discharges in the critically ill: A case-control study of 200 patients.","volume":"79","author":"Foreman","year":"2012","journal-title":"Neurology"},{"key":"R31-20260211","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1212\/01.wnl.0000499649.36058.c0","article-title":"Antibiotic-associated encephalopathy.","volume":"87","author":"Stip","year":"2016","journal-title":"Neurology"},{"key":"R32-20260211","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/1941874418803225","article-title":"Cefepime-induced encephalopathy and nonconvulsive status epilepticus: Dispelling an artificial dichotomy.","volume":"9","author":"Tchapyjnikov","year":"2019","journal-title":"Neurohospitalist"},{"key":"R33-20260211","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society.","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R34-20260211","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections.","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000001380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:00:11Z","timestamp":1770822011000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000001380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000001380","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}